Navigation Links
PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
Date:6/21/2010

MONTEREY, Calif., June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved.  Patients receiving Cayston had a mean increase in FEV(1) percent predicted from baseline to day 28 of 8.35 percent compared to 0.55 percent for patients receiving tobramycin inhalation solution, meeting the statistical definition of superiority for the Cayston and Altera combination.  Safety results were similar across both arms of the study, with lower incidence of cough in patients receiving Cayston.  This data was presented by Gilead Sciences during a late-breaker oral session on Friday at the 33rd European Cystic Fibrosis Conference (ECFC).  

In the study, 268 patients were randomized to receive Cayston or tobramycin inhalation solution over a 24-week treatment period.  Approximately 85 percent of patients in the study had received at least three courses of inhaled tobramycin in the 12 months prior to randomization.  Final six-month study results will become available for presentation later this year.

"We are very pleased to see these encouraging results.  Our goal is to improve therapies for respiratory care using our advanced aerosol delivery platforms, such as eFlow Technology.  In addition to aerosol delivery expertise, PARI Pharma also contributed to the initial formulation of Cayston and optimized the formulation to the Altera Nebulizer System.  As evidenced in multiple clinical trials, Altera delivers Cayston in two to three minutes – a significant reduc
'/>"/>

SOURCE PARI Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
4. Pharmasset Reports Fiscal Year End 2009 Financial Results
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
7. Sosei Assigns AD 923 Assets to Pharmasol
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
10. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
11. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., a ... has launched the FreeRunner™ knee brace with new ... from patella mal-tracking return to active lifestyles.  FreeRunner,s ... other braces, providing support when patients need it ... they don,t. Patellofemoral issues are the ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... and IRVINE, Calif., May 6, 2011 CryoLife, Inc. ... device and cardiovascular tissue processing company, today announced the ... through its wholly owned subsidiary CL Falcon, Inc., for ... ("Cardiogenesis") (OTCQB: CGCP).  The tender offer expired at 12:00 ...
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Reducing the number ... incidence of Lyme disease and other tick-borne infections among ... deer populations can be manipulated to reduce human interactions ... contracting Lyme disease," the researchers wrote. White-tailed deer ... transmit Lyme disease to people. The study included ...
(Date:7/11/2014)... 11, 2014 Volunteers from Scientology ... abuse this week with drug education lectures, forums and ... distribution in cities around the world. , Drug abuse ... Institute on Drug Abuse, abuse of alcohol and illicit ... crime, lost work, decreased productivity and healthcare. , ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... by Types, Applications & Geography - 2018,” defines ... fiber market with an analysis and forecast of ... specialty synthetic fibers (Para aramids, meta aramids, UHMW ... others including PPS fiber, PBI fiber, PBO fiber, ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2
... ... ... ... ...
... , ... ... ... ...
... ... ... , ... , , ...
... ... ... , , ... WASHINGTON , ...
... type of blood cancer, mixed lineage leukemia (MLL), has an ... cells rely on the normal version of an associated protein ... of chromosome 11 breaks off at the normal MLL-associated gene. ... a fusion protein that eventually causes uncontrolled growth of blood ...
... ... Health Systems. The Meaningful Use Dashboard will provide a single location where an organization ... Indicators. , ... OH (PRWEB) February 26, 2010 -- Health Care DataWorks , a Technology Company ...
Cached Medicine News:Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 2Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 3Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 4Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 5Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 6Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 7Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 8Health News:CPR Instruction Via Cell Phone Effective 2Health News:CPR Instruction Via Cell Phone Effective 3Health News:CPR Instruction Via Cell Phone Effective 4Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 2Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 3Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 2Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 3Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 5Health News:Cells of aggressive leukemia hijack normal protein to grow 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: